Mylan Inc. MYL today
announced that it has entered into a settlement agreement with Shionogi Inc.
and CIMA Labs Inc. that will resolve patent litigation related to Prednisolone
Sodium Phosphate Orally Disintegrating Tablets (ODT), 10 mg, 15 mg and 30 mg.
Prednisolone Sodium Phosphate ODT is the generic version of Shionogi's Orapred
ODT^®, which is indicated for the treatment of certain pulmonary diseases such
as asthma. Additionally, the product is indicated for the control of certain
severe or incapacitating allergic conditions, such as atopic dermatitis, and
seasonal and perennial allergic rhinitis, that are intractable to adequate
trials of conventional treatment.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in